Opioid antagonism modulates wanting-related frontostriatal connectivity.  Soutschek A, Weber SC, Kahnt T, Quednow BB, Tobler PN.  Elife. 2021 Nov 11;10:e71077. doi: 10.7554/eLife.71077. PMID: 34761749; PMCID: PMC8598157. https://www.ncb…

Perspectives on extended-release naltrexone induction among patients living with HIV and opioid use disorder: a qualitative analysis.  Hoffman KA, Baker R, Fanucchi LC, Lum PJ, Kunkel LE, Ponce Terashima J, McCarty D, Jacobs P, Korthuis PT.&nb…

Life satisfaction among individuals with opioid use disorder receiving extended-release naltrexone: A 12-week randomized controlled trial and a 36-week follow-up Gaulen, Zhanna et al. Journal of Substance Abuse Treatment, Volume 0, Issue 0, 108656…

Is extended release naltrexone superior to buprenorphine-naloxone to reduce drinking among outpatients receiving treatment for opioid use disorder? A secondary analysis of the CTN X:BOT trial.  Roache, J.D., Pavlicova, M., Campbell, A., Choo…

Levels of Impulsivity, Hyperactivity, and Inattention and the Association with Mental Health and Substance Use Severity in Opioid-Dependent Patients Seeking Treatment with Extended-Release Naltrexone.  Karlsson AT, Vederhus JK, Clausen T, Weim…

Low-Dose Naltrexone Co-Treatment in the Prevention of Opioid-Induced Hyperalgesia.  Shaheed G, Manjooran AP, Reddy AJ, Nawathey N, Habib S, Brahmbhatt H.  Cureus. 2021 Sep 2;13(9):e17667. doi: 10.7759/cureus.17667. PMID: 34646707; PMCID…